DeMatteo Lab

SELECTED PUBLICATIONS

2009

Gold, J. S., M. Gonen, A. Gutierrez, J. M. Broto, X. Garcia-del-Muro, T. C. Smyrk, R. G. Maki, S. Singer, M. F. Brennan, C. R. Antonescu, J. H. Donohue, and R. P. DeMatteo. 2009. ‘Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis’, Lancet Oncol, 10: 1045-52.

Dematteo, R. P., K. V. Ballman, C. R. Antonescu, R. G. Maki, P. W. Pisters, G. D. Demetri, M. E. Blackstein, C. D. Blanke, M. von Mehren, M. F. Brennan, S. Patel, M. D. McCarter, J. A. Polikoff, B. R. Tan, K. Owzar, and Gist Study Team American College of Surgeons Oncology Group Intergroup Adjuvant. 2009. ‘Adjuvant imati-nib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial’, Lancet, 373: 1097-104.


2011

Balachandran, V. P., M. J. Cavnar, S. Zeng, Z. M. Bamboat, L. M. Ocuin, H. Obaid, E. C. Sorenson, R. Popow, C. Ariyan, F. Rossi, P. Besmer, T. Guo, C. R. Antonescu, T. Taguchi, J. Yuan, J. D. Wolchok, J. P. Allison, and R. P. DeMatteo. 2011. ‘Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido’, Nat Med, 17: 1094-100.


2012

McCarter, M. D., C. R. Antonescu, K. V. Ballman, R. G. Maki, P. W. Pisters, G. D. Demetri, C. D. Blanke, M. von Mehren, M. F. Brennan, L. McCall, D. M. Ota, R. P. DeMatteo, and Team American College of Surgeons Oncol-ogy Group Intergroup Adjuvant Gist Study. 2012. ‘Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence’, J Am Coll Surg, 215: 53-9; discussion 59-60.


2013

Cavnar, M. J., S. Zeng, T. S. Kim, E. C. Sorenson, L. M. Ocuin, V. P. Balachandran, A. M. Seifert, J. B. Greer, R. Popow, M. H. Crawley, N. A. Cohen, B. L. Green, F. Rossi, P. Besmer, C. R. Antonescu, and R. P. DeMatteo. 2013. ‘KIT oncogene inhibition drives intratumoral macrophage M2 polarization’, J Exp Med, 210: 2873-86.


2014

Kim, T. S., M. J. Cavnar, N. A. Cohen, E. C. Sorenson, J. B. Greer, A. M. Seifert, M. H. Crawley, B. L. Green, R. Popow, N. Pillarsetty, D. R. Veach, A. T. Ku, F. Rossi, P. Besmer, C. R. Antonescu, S. Zeng, and R. P. Dematteo. 2014. ‘Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor’, Clin Can-cer Res, 20: 2350-62.

Corless, C. L., K. V. Ballman, C. R. Antonescu, V. Kolesnikova, R. G. Maki, P. W. Pisters, M. E. Blackstein, C. D. Blanke, G. D. Demetri, M. C. Heinrich, M. von Mehren, S. Patel, M. D. McCarter, K. Owzar, and R. P. DeMatteo. 2014. ‘Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial’, J Clin Oncol, 32: 1563-70.


2015

Cohen, N. A., S. Zeng, A. M. Seifert, T. S. Kim, E. C. Sorenson, J. B. Greer, M. J. Beckman, J. A. Santamaria-Barria, M. H. Crawley, B. L. Green, F. Rossi, P. Besmer, C. R. Antonescu, and R. P. DeMatteo. 2015. ‘Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors’, Cancer Res, 75: 2061-70.


2017

Zeng, S., A. M. Seifert, J. Q. Zhang, T. S. Kim, T. G. Bowler, M. J. Cavnar, B. D. Medina, G. A. Vitiello, F. Rossi, J. K. Loo, N. J. Param, and R. P. DeMatteo. 2017. ‘ETV4 collaborates with Wnt/beta-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor’, Oncotarget, 8: 114195-209.

Seifert, A. M., S. Zeng, J. Q. Zhang, T. S. Kim, N. A. Cohen, M. J. Beckman, B. D. Medina, J. H. Maltbaek, J. K. Loo, M. H. Crawley, F. Rossi, P. Besmer, C. R. Antonescu, and R. P. DeMatteo. 2017. ‘PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors’, Clin Cancer Res, 23: 454-65.

Bosbach, B., F. Rossi, Y. Yozgat, J. Loo, J. Q. Zhang, G. Berrozpe, K. Warpinski, I. Ehlers, D. Veach, A. Kwok, K. Manova, C. R. Antonescu, R. P. DeMatteo, and P. Besmer. 2017. ‘Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor’, Proc Natl Acad Sci U S A, 114: E8448-E57.

Zeng, S., A. M. Seifert, J. Q. Zhang, M. J. Cavnar, T. S. Kim, V. P. Balachandran, J. A. Santamaria-Barria, N. A. Cohen, M. J. Beckman, B. D. Medina, F. Rossi, M. H. Crawley, J. K. Loo, J. H. Maltbaek, P. Besmer, C. R. Antonescu, and R. P. DeMatteo. 2017. ‘Wnt/beta-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor’, Mol Cancer Ther, 16: 1954-66.


2018

Vitiello, G. A., B. D. Medina, S. Zeng, T. G. Bowler, J. Q. Zhang, J. K. Loo, N. J. Param, M. Liu, A. J. Moral, J. N. Zhao, F. Rossi, C. R. Antonescu, V. P. Balachandran, J. R. Cross, and R. P. DeMatteo. 2018. ‘Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor’, Clin Cancer Res, 24: 972-84.

Zhang, J. Q., S. Zeng, G. A. Vitiello, A. M. Seifert, B. D. Medina, M. J. Beckman, J. Loo, J. Santamaria-Barria, J. H. Maltbaek, N. J. Param, J. A. Moral, J. N. Zhao, V. Balachandran, F. Rossi, C. R. Antonescu, and R. P. DeMatteo. 2018. ‘Macrophages and CD8+ T cells mediate the anti-tumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors’, Cancer Immunol Res.


2019

Medina, B. D., M. Liu, G. A. Vitiello, A. M. Seifert, S. Zeng, T. Bowler, J. Q. Zhang, M. J. Cavnar, J. K. Loo, N. J. Param, J. H. Maltbaek, F. Rossi, V. Balachandran, and R. P. DeMatteo. 2019. 'Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity', J Exp Med.

Cavnar, M. J., K. Seier, C. Curtin, V. P. Balachandran, D. G. Coit, S. S. Yoon, A. M. Crago, V. E. Strong, W. D. Tap, M. Gonen, C. R. Antonescu, M. F. Brennan, S. Singer, and R. P. DeMatteo. 2019. 'Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre and Post-imatinib Eras', Ann Surg.

Etherington, M. S., and R. P. DeMatteo. 2019. 'Tailored management of primary gastrointestinal stromal tumors', Cancer.

Vitiello, G. A., T. G. Bowler, M. Liu, B. D. Medina, J. Q. Zhang, N. J. Param, J. K. Loo, R. L. Goldfeder, F. Chibon, F. Rossi, S. Zeng, and R. P. DeMatteo. 2019. 'Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor', J Clin Invest.


2020

Zhang, Jennifer Q., Benedikt Bosbach, Jennifer K. Loo, Gerardo A. Vitiello, Shan Zeng, Adrian M. Seifert, Benjamin D. Medina, Nesteene J. Param, Joanna H. Maltbaek, Ferdinand Rossi, Cristina R. Antonescu, Peter Besmer, and Ronald P. DeMatteo. 2020. "The V654A Second-site KIT Mutation Increases Tumor Oncogenesis and STAT Activation in a Mouse Model of Gastrointestinal Stromal Tumor." Oncogene, 39.49: 7153-165.

Moral, John Alec, Joanne Leung, Luis A. Rojas, Jennifer Ruan, Julia Zhao, Zachary Sethna, Anita Ramnarain, Billel Gasmi, Murali Gururajan, David Redmond, Gokce Askan, Umesh Bhanot, Ela Elyada, Youngkyu Park, David A. Tuveson, Mithat Gönen, Steven D. Leach, Jedd D. Wolchok, Ronald P. DeMatteo, Taha Merghoub, and Vinod P. Balachandran. 2020. "ILC2s Amplify PD-1 Blockade by Activating Tissue-specific Cancer Immunity." Nature, 579.7797: 130-35.


2021

Liu, Mengyuan, Mark S. Etherington, Andrew Hanna, Benjamin D. Medina, Gerardo A. Vitiello, Timothy G. Bowler, Nesteene J. Param, Lillian Levin, Ferdinand Rossi, and Ronald P. DeMatteo. 2021. "Oncogenic KIT Modulates Type I IFN–Mediated Antitumor Immunity in GIST." Cancer Immunology Research.

Ye, Shuai, Dinara Sharipova, Marya Kozinova, Lilli Klug, Jimson D’Souza, Martin G. Belinsky, Katherine J. Johnson, Margret B. Einarson, Karthik Devarajan, Yan Zhou, Samuel Litwin, Michael C. Heinrich, Ronald DeMatteo, Margaret Von Mehren, James S. Duncan, and Lori Rink. 2021. "Identification of Wee1 as a Target in Combination with Avapritinib for Gastrointestinal Stromal Tumor Treatment." JCI Insight, 6.2.

Our research is made possible with generous donations from the David Foundation,
Betsy Levine Brown and Marc Brown, and the GIST Cancer Research Fund.